As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting articles on pediatric CML and from low- and middle-income countries.

Read Professor Hughes' CML publications of the month: September 2023

Clinical CML papers

• Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
  Kok CH et al. Blood Cancer J, Sept 2023 (epub ahead of print) – open access publication
  
• Survival with chronic myeloid leukemia after failing milestones
  Lauseker M et al. Leukemia, September 2023 (epub ahead of print) – open access publication
  
• Treatment-free remission after dasatinib in patients with chronic myeloid leukemia in chronic-phase with deep molecular response: Final 5-year analysis of DASFREE
  Shah NP et al. Br J Haematol, Sept 2023 - open access publication
• The (near) miracle of therapy in chronic myeloid leukemia
  Radich JP. Br J Haematol, Sept 2023 – open access publication
• Improvement, implementation, and evaluation of the CMyLife Digital Care Platform: Participatory Action Research Approach
  Verweij L et al. J Med Internet Res, Sept 2023 - open access publication
  
• BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population
  Kockerols C et al. Eur J Haematol, Sept 2023 (epub ahead of print)
• External validation of the predictive scoring systems for molecular responses in chronic myeloid leukemia receiving initial imatinib therapy
  Qi F et al. Leukemia, Sept 2023
• Final report of TKI discontinuation trial with dasatinib for the second attempts of treatment-free remission after failing the first attempts with imatinb: Treatment-free Remission Accomplished by Dasatinib (TRAD) Study
  Perusini MA et al. Br J Haematol, Sept 2023 (epub ahead of print)
• Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukemia
  Del Rosario García B et al. J Oncol Pharm Pract, Sept 2023 (epub ahead of print)
• The expanding CML treatment landscape: an introspective commentary
  Lipton JH, Blood Cancer J, Sept 2023 (epub ahead of print) – open access publication

Scientific CML papers

• Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
  Shanmunagathan N et al. Haematologica, Sept 2023 – open access publication
  
• New patterns of genetic instability in chronic myeloid leukemia: Interesting, but not ready for clinical use
  Schiffer CA. Haematologica, Sept 2023 – open access publication
• Aquired miR-142 deficit in leukemia stem cells suffices to drive chronic myeloid leukemia into blast crisis
  Zhang B et al. Nat Commun, Sept 2023 – open access publication
• Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells
  Okabe S and Gotoh A. BMC Cancer, Sept 2023

Pediatric CML papers

• Priapism at diagnosis of pediatric chronic myeloid leukemia: Data derived from a large cohort of children and teenagers and a narrative review on priapism management
  Suttorp M et al. J Clin Med, July 2023 – open access publication
• Somatic variant profiling in chronic phase pediatric CML
  Behrens YL et al. Haematologica, Sept 2023 (epub ahead of print) – open access publication
• The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study
  Hijiya N et al. Blood Adv, Sept 2023 (epub ahead of print

LMIC CML papers

• Population pharmacokinetics and pharmacogenetics analyses of dasatinib in Chinese patients with chronic myeloid leukemia
  He S et al. Pharm Res, Sept 2023 (epub ahead of print)